OxyContin and the Origins of the Opioid Epidemic
This paper examines the role of OxyContin in triggering the opioid epidemic in the United States, beginning with Purdue Pharma's 1996 launch and subsequent guilty plea for misleading the public about addiction risks. It analyzes the drug's broad social impact, including links to heroin use, rising death rates, and health disparities between White and Black communities. The paper also reviews evidence-based treatment approaches for opioid use disorder, focusing on medications such as methadone and buprenorphine, relapse prevention strategies, cognitive behavioral therapy, and the importance of public health education and government-led awareness campaigns.
- Introduction: OxyContin and the Rise of Opioid Misuse: OxyContin launch and Purdue Pharma's misconduct
- Social Impact of OxyContin Over-Prescription: Death rates, racial disparities, and social determinants
- Treatment Options for Opioid Use Disorder: Methadone and buprenorphine as evidence-based treatments
- Recovery Strategies and Public Health Education: Relapse prevention, therapy, and government awareness campaigns
✍️ How to write this paper — guide, tools & examples ▾
What makes this paper effective
- The paper grounds its argument in documented legal consequences, citing Purdue Pharma's 2007 guilty plea and $365 million settlement to establish corporate accountability as a root cause of the epidemic.
- It integrates a social determinants framework, connecting opioid misuse to poverty, chronic pain, depression, and racial healthcare disparities, which adds analytical depth beyond a purely clinical account.
- The transition from problem to solution is clear and logical — the paper moves from social impact directly into evidence-based treatments and ends with actionable policy recommendations.
Key academic technique demonstrated
The paper demonstrates cause-and-effect argumentation supported by peer-reviewed sources and government data. By citing a comparative study on relapse factors (Kadam et al., 2017) alongside CDC treatment guidance, the author shows how to blend clinical evidence with public health policy to build a well-rounded argument.
Structure breakdown
The paper is organized into two main content sections — social impact and treatment — preceded by a contextualizing introduction. The first section establishes the historical and social dimensions of the epidemic; the second shifts to individual and systemic solutions. A brief reference to public health education closes the argument with a forward-looking recommendation, giving the paper a clear problem–analysis–solution arc.
Introduction: OxyContin and the Rise of Opioid Misuse
Opioids are a class of drugs that includes the illegal substance heroin. When the over-prescription of OxyContin was first observed, it was directly linked to growing addiction to heroin. Purdue Pharma launched OxyContin in 1996 with extensive marketing targeting primary care physicians, who began advising patients suffering from back pain and knee pain to use the drug (Ryan, 2016). It was soon noticed that the effects of this best-selling painkiller wore off earlier than expected, prompting patients to seek more pills whenever they needed relief. Purdue Pharma was found guilty in 2007 of misleading the federal government and consumers about the risks of OxyContin misuse. The company had been downplaying the drug's addiction potential and was required to pay $365 million in compensation.
Social Impact of OxyContin Over-Prescription
The overuse of heroin has been linked to spiking death rates between 2010 and 2015, and the use of legal opioids was connected to seven out of ten reports of death or injury (Dasgupta, Beletsky, & Ciccarone, 2018). The social determinants of this overuse have causal connections with poor health, obesity, alcohol use, depression, and chronic pain. The most prominent factor underlying these root causes appears to be social distress, which in severe cases leads to suicide through overdose.
When physicians frequently encountered patients experiencing stress and pain, they continued prescribing painkillers like OxyContin based on the frequency of pain episodes, dosing schedules, medication potency, and other related factors. Furthermore, structured access to U.S. healthcare along racial lines meant that white patients did not show equally high rates of opioid use, while Black patients remained disadvantaged — lacking access to quality healthcare and being left with painkiller prescriptions as a primary form of treatment. The social impact of the epidemic continued to deteriorate, requiring urgent intervention. Eliminating opioid use disorder called for corrected medications such as methadone and buprenorphine for more rapid improvements. In this context, healthcare providers must focus on alleviating patient suffering with compassion and without discrimination, rather than defaulting to opioids as the primary means of pain management.
Treatment Options for Opioid Use Disorder
Methadone and buprenorphine are both appropriate medications for reducing the effects of opioid dependence and heroin addiction. A study revealed that people dependent on opioids develop an extremely high craving for the substance — stronger even than the craving associated with alcohol dependence (Kadam et al., 2017). Opioid use disorder is a chronic, relapsing condition that is difficult for those affected to overcome. It alters brain chemistry and disrupts the body's normal functioning, making it hard for individuals to concentrate on daily activities at school or at home. It also undermines the healthy maintenance of relationships and can ultimately lead to overdose and death.
Methadone is available in liquid form and can be taken daily; however, it must be administered within a certified opioid treatment program (Centers for Disease Control and Prevention, n.d.). Buprenorphine is available as a dissolving tablet, a six-month implant placed beneath the skin, or a cheek film. Unlike methadone, buprenorphine is approved for use outside of a clinic setting. Both medications form the cornerstone of medication-assisted treatment for opioid use disorder.
References
Centers for Disease Control and Prevention. (n.d.). Rx awareness: Recovery is possible. Retrieved from https://www.cdc.gov/rxawareness/treatment/index.html
Dasgupta, N., Beletsky, L., & Ciccarone, D. (2018). Opioid crisis: No easy fix to its social and economic determinants. American Journal of Public Health, 108(2), 182–186.
Kadam, M., Sinha, A., Nimkar, S., Matcheswalla, Y., & De Sousa, A. (2017). A comparative study of factors associated with relapse in alcohol dependence and opioid dependence. Indian Journal of Psychological Medicine, 39(5), 627–633.
Ryan, H. (2016, May 27). Senator calls for investigation of Purdue Pharma following Times story on OxyContin. Los Angeles Times. Retrieved from https://www.latimes.com/projects/la-me-oxycontin-full-coverage/
Create your account
Always verify citation format against your institution’s current style guide requirements.